Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1967 1
1968 1
1975 4
1976 2
1977 3
1978 5
1979 14
1980 22
1981 29
1982 39
1983 44
1984 77
1985 91
1986 106
1987 143
1988 134
1989 203
1990 159
1991 168
1992 184
1993 189
1994 182
1995 175
1996 183
1997 188
1998 179
1999 211
2000 208
2001 186
2002 208
2003 253
2004 243
2005 279
2006 362
2007 379
2008 445
2009 494
2010 516
2011 525
2012 614
2013 781
2014 708
2015 719
2016 729
2017 758
2018 748
2019 820
2020 862
2021 856
2022 762
2023 732
2024 665
2025 698
2026 582
2027 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,901 results

Results by year

Filters applied: . Clear all
Page 1
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, May HT, Shaikh K, Shekar C, Roy SK, Tayek J, Nelson JR. Budoff MJ, et al. Eur Heart J. 2020 Oct 21;41(40):3925-3932. doi: 10.1093/eurheartj/ehaa652. Eur Heart J. 2020. PMID: 32860032 Free PMC article. Clinical Trial.
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant cardiovascular (CV) risk remains. Icosapent ethyl (IPE), a highly purified eicosapentaenoic acid ethyl ester, added to a st …
AIMS: Despite the effects of statins in reducing cardiovascular events and slowing progression of coronary atherosclerosis, significant card …
Importance of EPA and DHA Blood Levels in Brain Structure and Function.
von Schacky C. von Schacky C. Nutrients. 2021 Mar 25;13(4):1074. doi: 10.3390/nu13041074. Nutrients. 2021. PMID: 33806218 Free PMC article. Review.
Brain structure and function depend on a constant and sufficient supply with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) by blood. Blood levels of EPA and DHA reflect dietary intake and other variables and are preferably assessed as percentage …
Brain structure and function depend on a constant and sufficient supply with eicosapentaenoic acid (EPA) and docosahexaenoic …
Can EPA evaporate plaques?
Tokgozoglu L, Catapano AL. Tokgozoglu L, et al. Eur Heart J. 2020 Oct 21;41(40):3933-3935. doi: 10.1093/eurheartj/ehaa750. Eur Heart J. 2020. PMID: 33141163 Free article. No abstract available.
Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).
Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H; RESPECT-EPA Investigators. Miyauchi K, et al. Circulation. 2024 Aug 6;150(6):425-434. doi: 10.1161/CIRCULATIONAHA.123.065520. Epub 2024 Jun 14. Circulation. 2024. PMID: 38873793 Clinical Trial.
BACKGROUND: Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to assess the clinical benefits of icosapent ethyl in patients with coronary artery disease, a low EPA/arachidonic acid (AA) ratio, …
BACKGROUND: Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to as …
Omega-3 Fatty Acids and Arrhythmias.
Marcus MD, Link MS. Marcus MD, et al. Circulation. 2024 Aug 6;150(6):488-503. doi: 10.1161/CIRCULATIONAHA.123.065769. Epub 2024 Aug 5. Circulation. 2024. PMID: 39102482 Review.
Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been widely replicated, and the potential of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) to reduce arrhythmic d …
Two trials that tested moderate and high-dose n-3 PUFA demonstrated a reduction in sudden cardiac death, but these findings have not been wi …
When to lower triglycerides?
Ganda OP. Ganda OP. Curr Opin Lipidol. 2020 Aug;31(4):238-245. doi: 10.1097/MOL.0000000000000694. Curr Opin Lipidol. 2020. PMID: 32520780 Review.
Trials with fibrates, and niacin to reduce residual dyslipidemia have not provided evidence of benefits after statin therapy, thus far. A recent trial with an omega 3 fatty acid (OM3FA), icosapent-ethyl (IPE), provided evidence for a 25% reduction in ASCVD events in …
Trials with fibrates, and niacin to reduce residual dyslipidemia have not provided evidence of benefits after statin therapy, thus far. A re …
Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1-induced platelet reactivity.
Mourikis P, Benkhoff M, Wildeis L, Barcik M, Helten C, Coman C, Solari FA, Krahn D, Dannenberg L, Ahlbrecht S, Zikeli D, Utz A, Trojovsky K, Richter H, Al Kassis G, M'Pembele R, Zako S, Huckenbeck T, Bauer S, Schmitz D, Pfeiler S, Gerdes N, Dücker C, Pircher J, Zhe Z, Thienel M, Ul Ain Q, Keul P, Kirkby N, Sohn D, Budach W, Hohlfeld T, Schrör K, Levkau B, Zeus T, Verhelst SHL, Ahrends R, Sickmann A, Mitchell J, Mora S, Manson JE, Bhatt DL, Landmesser U, Massberg S, Kelm M, Petzold T, Polzin A. Mourikis P, et al. Sci Transl Med. 2025 May 21;17(799):eado0610. doi: 10.1126/scitranslmed.ado0610. Epub 2025 May 21. Sci Transl Med. 2025. PMID: 40397711
Large, randomized trials testing omega-3 polyunsaturated fatty acid (omega-3 PUFA) supplementation to reduce cardiovascular events have reported contradictory results. ...We also investigated the effects of omega-3 PUFA in rodent models of arterial thrombosis and in tail b …
Large, randomized trials testing omega-3 polyunsaturated fatty acid (omega-3 PUFA) supplementation to reduce cardiovascular events ha …
[Eicosapentaenoic acid].
Tsushima M. Tsushima M. Nihon Rinsho. 2001 Mar;59 Suppl 3:650-6. Nihon Rinsho. 2001. PMID: 11347148 Review. Japanese. No abstract available.
[Icosapentate (EPA)].
Katayama Y, Katsumata T. Katayama Y, et al. Nihon Rinsho. 1999 Sep;57 Suppl:114-6. Nihon Rinsho. 1999. PMID: 10543064 Review. Japanese. No abstract available.
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Ketchum SB, Lira Pineda A, Doyle RT Jr, Steg PG; REDUCE-IT Investigators. Szarek M, et al. J Am Coll Cardiol. 2024 Apr 23;83(16):1529-1539. doi: 10.1016/j.jacc.2024.02.016. Epub 2024 Mar 25. J Am Coll Cardiol. 2024. PMID: 38530686 Free article. Clinical Trial.
OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was to explore the cardiovascular benefit of icosapent ethyl (IPE) across a range of Lp(a) levels. ...
OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Tria …
15,901 results
You have reached the last available page of results. Please see the User Guide for more information.